Overdosage with colestipol has not been reported FDA Label, L6115, F4555, F4567. Regardless, in the case of overdosage, the chief potential harm would be obstruction of the gastrointestinal tract FDA Label, L6115, F4555, F4567. The location of such potential obstruction, the degree of obstruction and the presence or absence of normal gut motility would determine treatment FDA Label, L6115, F4555, F4567.
No clinical data are available on the use of colestipol in pregnant women and during lactation FDA Label, L6115, F4555, F4567. Colestipol does not appear to be absorbed systematically FDA Label, L6115, F4555, F4567. Due to its known interference with absorption of fat-soluble vitamins, the use of colestipol in pregnancy or lactation or by women of childbearing potential requires that the benefits of drug therapy be weighed against the possible hazards to the mother and the child FDA Label, L6115, F4555, F4567.
There are no data on the effect of colestipol on fertility in humans FDA Label, L6115, F4555, F4567.
The use of colestipol in children is limited FDA Label, L6115, F4555, F4567. Clinical trials conducted in children with colestipol ranules have usually employed doses of 5 to 20 g/day FDA Label, L6115, F4555, F4567. The National Cholesterol Education Program (NCEP) Expert Panel recommends drug therapy be considered in children 10 years or older, who have previously undergone an adequate trial of diet therapy but still have unacceptably high serum cholesterol levels FDA Label, L6115, F4555, F4567. In certain situations where a young child has extremely high serum cholesterol levels, drug treatment may even be initiated before 10 years of age FDA Label, L6115, F4555, F4567. If the child is started on drug therapy, a carefully assessed diet therapy should also be continued in order to obtain optimal results FDA Label, L6115, F4555, F4567. However, the safety of using colestipol tablets in patients under the age of 18 years has not been established FDA Label, L6115, F4555, F4567. Furthermore, because bile acid sequestrants like colestipol may interfere with the absorption of fat-soluble vitamins, appropriate monitoring of growth and development is essential if colestipol is used in children FDA Label, L6115, F4555, F4567.
Appropriate studies on the relationship of age to the effects of colestipol have not been performed in the geriatric population FDA Label, L6115, F4555, F4567. However, patients over 60 years of age may be more likely to experience gastrointestinal side effects, as well as adverse nutritional effects FDA Label, L6115, F4555, F4567.
Additionally, it has been determined that the oral LD50 in rats is > 1000 mg/kg MSDS.
Bile acid sequestrants like colestipol have been in use since the 1970s.FDA Label, F4555, F4567, L6262 And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally only employed as an adjunct therapy and the relatively physical nature of its pharmacological activity sometimes limits its usefulness.FDA Label, F4555, F4567, L6262
In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut.FDA Label, F4555, F4567, L6262
Alternatively, colestipol predominantly elicits its activities within the gut environment because it undergoes little absorption and metabolism.FDA Label, F4555, F4567, L6262 The resultant lack of systemic exposure consequently means the medication generally demonstrates very few adverse effects inside the body.FDA Label, F4555, F4567, L6262
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diltiazem | Colestipol can cause a decrease in the absorption of Diltiazem resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Amiodarone | The excretion of Amiodarone can be increased when combined with Colestipol. |
| Pravastatin | Colestipol can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lovastatin | Colestipol can cause a decrease in the absorption of Lovastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cerivastatin | Colestipol can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Simvastatin | Colestipol can cause a decrease in the absorption of Simvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Atorvastatin | Colestipol can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluvastatin | Colestipol can cause a decrease in the absorption of Fluvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosuvastatin | Colestipol can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mevastatin | Colestipol can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pitavastatin | Colestipol can cause a decrease in the absorption of Pitavastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ursodeoxycholic acid | Colestipol can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycochenodeoxycholic Acid | Colestipol can cause a decrease in the absorption of Glycochenodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholic Acid | Colestipol can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycocholic acid | Colestipol can cause a decrease in the absorption of Glycocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deoxycholic acid | Colestipol can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurocholic acid | Colestipol can cause a decrease in the absorption of Taurocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chenodeoxycholic acid | Colestipol can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurochenodeoxycholic acid | Colestipol can cause a decrease in the absorption of Taurochenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tauroursodeoxycholic acid | Colestipol can cause a decrease in the absorption of Tauroursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bamet-UD2 | Colestipol can cause a decrease in the absorption of Bamet-UD2 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dehydrocholic acid | Colestipol can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hyodeoxycholic Acid | Colestipol can cause a decrease in the absorption of Hyodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deferasirox | Colestipol can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ezetimibe | Colestipol can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Leflunomide | Colestipol may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy. |
| Teriflunomide | Colestipol may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy. |
| Lomitapide | Colestipol can cause a decrease in the absorption of Lomitapide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrexate | Colestipol may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy. |
| Niacin | Colestipol can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Propranolol | Colestipol can cause a decrease in the absorption of Propranolol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raloxifene | Colestipol can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Vancomycin | The therapeutic efficacy of Vancomycin can be decreased when used in combination with Colestipol. |
| Mycophenolate mofetil | Colestipol can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | Colestipol can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetyldigitoxin | Colestipol can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deslanoside | Colestipol can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ouabain | Colestipol can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Digitoxin | Colestipol can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oleandrin | Colestipol can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cymarin | Colestipol can cause a decrease in the absorption of Cymarin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Proscillaridin | Colestipol can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lanatoside C | Colestipol can cause a decrease in the absorption of Lanatoside C resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gitoformate | Colestipol can cause a decrease in the absorption of Gitoformate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Peruvoside | Colestipol can cause a decrease in the absorption of Peruvoside resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Desogestrel | Colestipol can cause a decrease in the absorption of Desogestrel resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Megestrol acetate | Colestipol can cause a decrease in the absorption of Megestrol acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levonorgestrel | Colestipol can cause a decrease in the absorption of Levonorgestrel resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Medroxyprogesterone acetate | Colestipol can cause a decrease in the absorption of Medroxyprogesterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norethisterone | Colestipol can cause a decrease in the absorption of Norethisterone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Estradiol | Colestipol can cause a decrease in the absorption of Estradiol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ethynodiol diacetate | Colestipol can cause a decrease in the absorption of Ethynodiol diacetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mifepristone | Colestipol can cause a decrease in the absorption of Mifepristone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norgestimate | Colestipol can cause a decrease in the absorption of Norgestimate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ethinylestradiol | Colestipol can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Drospirenone | Colestipol can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cyproterone acetate | Colestipol can cause a decrease in the absorption of Cyproterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gestodene | Colestipol can cause a decrease in the absorption of Gestodene resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dienogest | Colestipol can cause a decrease in the absorption of Dienogest resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norethynodrel | Colestipol can cause a decrease in the absorption of Norethynodrel resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norgestrel | Colestipol can cause a decrease in the absorption of Norgestrel resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gestrinone | Colestipol can cause a decrease in the absorption of Gestrinone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lynestrenol | Colestipol can cause a decrease in the absorption of Lynestrenol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ormeloxifene | Colestipol can cause a decrease in the absorption of Ormeloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chlormadinone | Colestipol can cause a decrease in the absorption of Chlormadinone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norgestrienone | Colestipol can cause a decrease in the absorption of Norgestrienone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Quingestanol | Colestipol can cause a decrease in the absorption of Quingestanol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Demegestone | Colestipol can cause a decrease in the absorption of Demegestone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nomegestrol acetate | Colestipol can cause a decrease in the absorption of Nomegestrol acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norethindrone enanthate | Colestipol can cause a decrease in the absorption of Norethindrone enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Estetrol | Colestipol can cause a decrease in the absorption of Estetrol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hydroxyprogesterone caproate | The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Colestipol. |
| Clofibrate | Colestipol can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fenofibrate | Colestipol can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gemfibrozil | Gemfibrozil can cause a decrease in the absorption of Colestipol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bezafibrate | Colestipol can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Etofibrate | Colestipol can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ciprofibrate | Colestipol can cause a decrease in the absorption of Ciprofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Simfibrate | Colestipol can cause a decrease in the absorption of Simfibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ronifibrate | Colestipol can cause a decrease in the absorption of Ronifibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium clofibrate | Colestipol can cause a decrease in the absorption of Aluminium clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clofibride | Colestipol can cause a decrease in the absorption of Clofibride resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fenofibric acid | Colestipol can cause a decrease in the absorption of Fenofibric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Icosapent | Colestipol can cause a decrease in the absorption of Icosapent resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indomethacin | Colestipol can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nabumetone | Colestipol can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ketorolac | Colestipol can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tenoxicam | Colestipol can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Celecoxib | Colestipol can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolmetin | Colestipol can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rofecoxib | Colestipol can cause a decrease in the absorption of Rofecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Piroxicam | Colestipol can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fenoprofen | Colestipol can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Valdecoxib | Colestipol can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Diclofenac | Colestipol can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sulindac | Colestipol can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Flurbiprofen | Colestipol can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Etodolac | Colestipol can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mefenamic acid | Colestipol can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Naproxen | Colestipol can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy. |